Bioequivalence study of two losartan formulations administered orally in healthy male volunteers

Arzneimittel-Forschung/Drug Research

Volumn 56, Issue 11, 2006, Pages 723-728

  Bienert, Agnieszka ^a   Brzeziński, Rafał ^a   Szałek, Edyta ^a   Dubai, Vitali ^a   Grześkowiak, Edmund ^a   Dyderski, Stanisław ^a   Drobnik, Leon ^a   Wolc, Anna ^b   Olejniczak Rabinek, Magdalena ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

Author keywords

Angiotensin receptor blocker; Antihypertensive agents; CAS 114798 26 4; Losartan, active metabolite, bioequivalence, pharmacokinetics

Indexed keywords

2 BUTYL 4 CHLORO 1 [4(2 1H TETRAZOL 5 YLPHENYL)BENZYL]IMIDAZOLE 5 METHANOL MONOPOTASSIUM; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CAS 114798 26 4; DRUG METABOLITE; LOSARTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

EID: 33845417266     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296781     Document Type: Article

References (13)

1. Conlin, P., Efficacy and Safety of Angiotensin Receptor Blockers: A Review of Losartan in Essential Hypertension. Curr. Ther. Res. Clin. Exp. 62, 79 (2001)
2. Appel, G. B., Appel, A. S., Angiotensin II receptor antagonists: Role in hypertension, cardiovascular disease, and renoprotection. Prog. Cardiovasc. Dis. 47, 105 (2004)
3. Harakambos, P G., Salerno, C. M., The Angiotensin II Type 1 Receptor Blocker Losartan in Clinical Practice: A Review. Clin. Ther. 6, 1058 (1996)
4. Ümit, Y., Forslund-Bergengren, C., Tybring, G. et al., Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin. Pharmacol. Ther. 71, 89 (2002)
5. Triggle, D. J., Angiotensin II receptor antagonism: Losartan - sites and mechanisms of action. Clin. Ther. 17, 1005 (1995)
6. McCrea, J. B., Cribb, A., Rushmore, T. et al., Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clin. Pharmacol. Ther. 65, 348 (1999)
7. Kirchheiner, J., Brockmöller, J., Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77, 1 (2005)
8. Cascorbi, I., Paul, M., Kroemer, H. K., Pharmacogenomics of heart failure - focus on drug disposition and action. Cardiovasc. Res. 64, 32 (2004)
9. Sica, D. A., Pharmacology and clinical efficacy of angiotensin receptor blockers. Am. J. Hypertens. 14 (Supp. 1), S242 (2001)
10. Burnier, M., Brunner, H. R., Angiotensin II receptor antagonists. Lancet 355, 637 (2000)
11. Weber, M., Clinical safety and tolerability of losartan. Clin. Ther. 19, 604 (1997)
12. Furtek, C. I., Lo, M. W., Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography. J. Chromatogr. 573, 295 (1992)
13. The European Agency for the Evalution of Medicinal Products Committee Proprietary Medical Pruducts; CPMP Note for Guidance of July 2001, CPMP/EWP/QWP/1401/98; The Investigation of Bioavailability and Bioequivalence